Hai-Yan Tu

429 total citations · 1 hit paper
5 papers, 271 citations indexed

About

Hai-Yan Tu is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Hai-Yan Tu has authored 5 papers receiving a total of 271 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Pulmonary and Respiratory Medicine, 4 papers in Oncology and 1 paper in Surgery. Recurrent topics in Hai-Yan Tu's work include Lung Cancer Treatments and Mutations (5 papers), Lung Cancer Diagnosis and Treatment (2 papers) and HER2/EGFR in Cancer Research (1 paper). Hai-Yan Tu is often cited by papers focused on Lung Cancer Treatments and Mutations (5 papers), Lung Cancer Diagnosis and Treatment (2 papers) and HER2/EGFR in Cancer Research (1 paper). Hai-Yan Tu collaborates with scholars based in China, United States and Netherlands. Hai-Yan Tu's co-authors include Yi‐Long Wu, Jianhua Chang, Jianying Zhou, Alexander Luft, Shun Lü, Christine Baudelet, Zhiyong Ma, Lin Wu, Yiping Zhang and Chengping Hu and has published in prestigious journals such as Journal of Thoracic Oncology, Clinical Lung Cancer and Oncology Letters.

In The Last Decade

Hai-Yan Tu

4 papers receiving 267 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial

2019 265 citations Yi‐Long Wu, Shun Lü et al. Journal of Thoracic Oncology profile →

Peers

Countries citing papers authored by Hai-Yan Tu

Since Specialization

Citations

This map shows the geographic impact of Hai-Yan Tu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hai-Yan Tu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hai-Yan Tu more than expected).

Fields of papers citing papers by Hai-Yan Tu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hai-Yan Tu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hai-Yan Tu. The network helps show where Hai-Yan Tu may publish in the future.

Co-authorship network of co-authors of Hai-Yan Tu

This figure shows the co-authorship network connecting the top 25 collaborators of Hai-Yan Tu. A scholar is included among the top collaborators of Hai-Yan Tu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hai-Yan Tu. Hai-Yan Tu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

5 of 5 papers shown

#	Work	Indexed citations
1	OA01.01 Beamion LUNG-1: Phase Ia/b Trial of HER2 Tyrosine Kinase Inhibitor Zongertinib (BI 1810631) in Patients with HER2 Aberration-Positive Solid Tumors 2024 ·Journal of Thoracic Oncology ·John V. Heymach, Noboru Yamamoto, Frans L. Opdam, Minal Barve, Hai-Yan Tu, Yi‐Long Wu, (unknown), (unknown), (unknown), (unknown), David Berz	0
2	PEARL: A Multicenter Phase 2 Study of Lorlatinib in Patients with ALK-Rearranged NSCLC and Central Nervous System Disease 2024 ·Clinical Lung Cancer ·(unknown), (unknown), Chanyuan Zhang, Shiyuan Chen, (unknown), (unknown), Chong‐Rui Xu, Hai-Yan Tu, (unknown), Qing Zhou, Xu‐Chao Zhang, Yi‐Long Wu, Weineng Feng, (unknown), (unknown)	1
3	Monitoring of Circulating Tumor DNA and Indication of De-Escalation Adjuvant Targeted Therapy for EGFR-Mutated NSCLC After Complete Resection 2024 ·JTO Clinical and Research Reports ·Song Dong, (unknown), Si‐Yang Liu, Xuan Gao, (unknown), Hongji Li, Wei Gao, (unknown), Si‐Yang Maggie Liu, Hai-Yan Tu, Yi Pan, Qing Zhou, Xue-Ning Yang, Xuefeng Xia, Xin Yi, (unknown), Yi‐Long Wu, Jia‐Tao Zhang	3
4	Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial breakdown → 2019 ·Journal of Thoracic Oncology ·Yi‐Long Wu, Shun Lü, Ying Cheng, Caicun Zhou, Jie Wang, Tony Mok, Li Zhang, Hai-Yan Tu, Lin Wu, Jifeng Feng, Yiping Zhang, Alexander Luft, Jianying Zhou, Zhiyong Ma, You Lü, Chengping Hu, Yuankai Shi, Christine Baudelet, Junliang Cai, Jianhua Chang	265
5	Responses to crizotinib in a patient with c-ros oncogene 1, receptor tyrosine kinase-positive advanced lung adenocarcinoma: A case report 2014 ·Oncology Letters ·Na Zhang, (unknown), Xu‐Chao Zhang, Zhi Xie, (unknown), Hai-Yan Tu, Ben‐Yuan Jiang, Yi‐Long Wu	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact